CVOTs of SGLT-2 inhibitors have consistently demonstrated cardiovascular risk reduction in the context of statin therapy, as well as slowing of kidney disease progression in the context of RAAS blockade therapy. The gene discussed is SLC5A2; the disease is kidney disorder.